← 返回前沿论文

TIL(肿瘤浸润淋巴细胞)与促炎生物标志物同乳腺癌分子亚型的关联:MEND 研究分析

英文原题:Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study.

查看英文原题

Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study.

PubMed 2026/07/10(内容时间) Breast Cancer Res Treat Q2 · IF 3.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

尼日利亚女性中,TILs 升高和 TNF-主导型特征与 TNBC(相较于 ER+)相关,这突显了免疫治疗在尼日利亚 TNBC 病例中的潜在相关性,以及 TNF-可能的预后/治疗作用。

研究思路结论见上方概要

TIL(肿瘤浸润淋巴细胞)(TILs)和促炎生物标志物影响乳腺癌(BC)的进展和结局。我们评估了尼日利亚女性中TILs与BC亚型之间的关联,并在探索性分析中评估了血清生物标志物(IL-6、IL-8、IL-1、TNF-和瘦素)、TILs与BC亚型之间的关系。

在436例未经治疗的尼日利亚BC患者的H&E染色肿瘤中量化了TIL,并通过Meso Scale Discovery免疫测定法对血清生物标志物(n = 109)进行了分析。使用描述性分析和多项逻辑回归评估了TIL和促炎生物标志物在不同BC亚型中的情况;还探索了细胞因子比值以表征TNF-优势。

中位年龄为49岁,亚型为三阴性(TNBC,43%)、luminal A(31%)、luminal B(12%)和HER2富集型(15%)。中位TIL百分比为10.0(Q1,Q3:4.0,21.0),其中49%的患者被归类为低TIL(< 10%),41%为中等(10- < 40%),10%为高(40%)。与低TIL相比,在人口学和临床调整后,中等TIL(OR 1.94,95% CI 1.11-3.38,p = 0.020)和高TIL(OR 2.65,95% CI 1.00-6.99,p = 0.049)与TNBC vs. ER+的更高比值比相关。TNF-与TILs相关(:0.21;p = 0.026),较高的TNF- :IL-1(OR 4.16,95% CI 1.35-12.84)和TNF- :IL-8(OR 3.81,95% CI 1.29-11.23)比值与TNBC相关,但与HER2无关(vs. ER+);单个生物标志物与亚型无关。

展开英文摘要原文

Tumor-infiltrating lymphocytes (TILs) and proinflammatory biomarkers shape breast cancer (BC) progression and outcomes. We estimated the association between TILs and BC subtypes in Nigerian women and, in exploratory analyses, evaluated relationships between serum biomarkers (IL-6, IL-8, IL-1 , TNF- , and leptin), TILs and BC subtypes.

TILs were quantified on H&E-stained tumors from 436 treatment-na ve Nigerian BC patients, serum biomarkers (n = 109) were profiled by Meso Scale Discovery immunoassays. TILs and proinflammatory biomarkers were assessed across BC subtypes using descriptive analyses and multinomial logistic regression; cytokine ratios were also explored to characterize TNF- dominance.

Median age was 49, and subtypes were triple-negative (TNBC, 43%), luminal A (31%), luminal B (12%), and HER2-enriched (15%). Median TIL percentage was 10.0 (Q1, Q3: 4.0, 21.0), with 49% of patients classified as low TIL (< 10%), 41% as intermediate (10- < 40%) and 10% as high ( 40%). Compared to low TILs, medium (OR 1.94, 95% CI 1.11-3.38, p = 0.020) and high TILs (OR 2.65, 95% CI 1.00-6.99, p = 0.049) were associated with higher odds of TNBC vs. ER+ after demographic and clinical adjustments. TNF- correlated with TILs ( : 0.21; p = 0.026) and higher TNF- :IL-1 (OR 4.16, 95% CI 1.35-12.84) and TNF- :IL-8 (OR 3.81, 95% CI 1.29-11.23) ratios were associated with TNBC but not HER2 (vs. ER+); individual biomarkers were not associated with subtypes.

Elevated TILs and TNF- -dominant profiles are associated with TNBC (vs. ER+) in Nigerian women, highlighting potential immunotherapy relevance in Nigerian TNBC cases and a suggestive prognostic/therapeutic role for TNF- .

论文信息

作者
Byemerwa J、Neish D、Forgah L、Deveaux A、Osazuwa-Peters O、Joshi A、Salako O、Daramola A
第一作者单位
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.United States
通讯作者单位
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA. tomi.akinyemiju@duke.edu.United States
期刊
Breast cancer research and treatment2026 Jul 10
原文标识
PubMed 42432165 · DOI 10.1007/s10549-026-08022-3